A total of 80 patients were involved in the study — 40 people were screened before the first COVID-19 lockdown, and 40 people were screened after.
Researchers found the median circulating tumor DNA concentration among patients diagnosed after the lockdown was higher than those diagnosed before lockdown.
The study suggests that CRC is a major area for intervention to minimize pandemic-associated delays in screening, diagnosis and treatment.
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.